Rejection of xenogeneic porcine islets in humanized mice is characterized by graft‐infiltrating Th17 cells and activated B cells

Frances T Lee,Anil Dangi,Sahil Shah,Melanie Burnette,Yong-Guang Yang,Allan D Kirk,Bernhard J Hering,Stephen D Miller,Xunrong Luo,Frances T. Lee,Yong‐Guang Yang,Allan D. Kirk,Bernhard J. Hering,Stephen D. Miller
DOI: https://doi.org/10.1111/ajt.15763
IF: 9.369
2020-01-21
American Journal of Transplantation
Abstract:Xenogeneic porcine islet transplantation is a promising potential therapy for type 1 diabetes (T1D). Understanding human immune responses against porcine islets is crucial for the design of optimal immunomodulatory regimens for effective control of xenogeneic rejection of porcine islets in humans. Humanized mice are a valuable tool for studying human immune responses and therefore present an attractive alternative to human subject research. Here, by using a pig‐to‐humanized mouse model of xenogeneic islet transplantation, we described the human immune response to transplanted porcine islets, a process characterized by dense islet xenograft infiltration of human CD45+ cells comprised of activated human B cells, CD4+CD44+IL‐17+ Th17 cells and CD68+ macrophages. We also tested an experimental immunomodulatory regimen in promoting long‐term islet xenograft survival, a triple therapy consisting of donor splenocytes treated with ethylcarbodiimide (ECDI‐SP), and peri‐transplant rituximab and rapamycin. We observed that the triple therapy effectively inhibited graft infiltration of T and B cells as well as macrophages, promoted transitional B cells both in the periphery and in the islet xenografts, and provided a superior islet xenograft protection. Our study therefore indicates an advantage of donor ECDI‐SP treatment in controlling human immune cells in promoting long‐term islet xenograft survival.
surgery,transplantation
What problem does this paper attempt to address?